These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 21615826)
21. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. Van Damme N; Deron P; Van Roy N; Demetter P; Bols A; Van Dorpe J; Baert F; Van Laethem JL; Speleman F; Pauwels P; Peeters M BMC Cancer; 2010 May; 10():189. PubMed ID: 20459770 [TBL] [Abstract][Full Text] [Related]
22. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718 [TBL] [Abstract][Full Text] [Related]
23. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883 [TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China. Zhou Y; Yang Y; Yang C; Chen Y; Yang C; Du Y; Zhao G; Guo Y; Ye L; Huang Y Oncotarget; 2017 Feb; 8(9):15023-15033. PubMed ID: 28107191 [TBL] [Abstract][Full Text] [Related]
25. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations. Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917 [TBL] [Abstract][Full Text] [Related]
26. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients. Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969 [TBL] [Abstract][Full Text] [Related]
27. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations. Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074 [TBL] [Abstract][Full Text] [Related]
28. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. Lai Y; Zhang Z; Li J; Sun D; Zhou Y; Jiang T; Han Y; Huang L; Zhu Y; Li X; Yan X Int J Mol Sci; 2013 Dec; 14(12):24549-59. PubMed ID: 24351833 [TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. Gou HF; Li X; Qiu M; Cheng K; Li LH; Dong H; Chen Y; Tang Y; Gao F; Zhao F; Men HT; Ge J; Su JM; Xu F; Bi F; Gao JJ; Liu JY PLoS One; 2013; 8(4):e62175. PubMed ID: 23637996 [TBL] [Abstract][Full Text] [Related]
30. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301 [TBL] [Abstract][Full Text] [Related]
31. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704 [TBL] [Abstract][Full Text] [Related]
32. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250 [TBL] [Abstract][Full Text] [Related]
34. Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid. Frankel D; Nanni-Metellus I; Robaglia-Schlupp A; Tomasini P; Guinde J; Barlesi F; Astoul P; Ouafik L; Amatore F; Secq V; Kaspi E; Roll P Clin Chem Lab Med; 2018 Apr; 56(5):851-856. PubMed ID: 29306909 [TBL] [Abstract][Full Text] [Related]
35. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases. Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971 [TBL] [Abstract][Full Text] [Related]
36. Liu SY; Chen W; Chughtai EA; Qiao Z; Jiang JT; Li SM; Zhang W; Zhang J World J Gastroenterol; 2017 Apr; 23(14):2585-2591. PubMed ID: 28465643 [TBL] [Abstract][Full Text] [Related]
37. EGFR and KRAS mutations in Chinese patients with sinonasal inverted papilloma and oncocytic papilloma. Wang H; Li H; Hu L; Zhou J; Zhai C; Wang D; Sun X Histopathology; 2019 Aug; 75(2):274-281. PubMed ID: 30916792 [TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia. Abedi-Ardekani B; Dar NA; Mir MM; Zargar SA; Lone MM; Martel-Planche G; Villar S; Mounawar M; Saidi F; Malekzadeh R; Hainaut P BMC Cancer; 2012 Dec; 12():602. PubMed ID: 23244191 [TBL] [Abstract][Full Text] [Related]
39. Melting curve analysis for mutations of EGFR and KRAS. Furugaki K; Yasuno H; Iwai T; Moriya Y; Harada N; Fujimoto-Ouchi K Anticancer Res; 2014 Feb; 34(2):613-21. PubMed ID: 24510990 [TBL] [Abstract][Full Text] [Related]
40. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]